First Human Results of the SELUTION Sirolimus Coated Balloon in Femoral-Popliteal Disease

Robert M. Bersin, MD, FACC, FSCAI
Swedish Heart and Vascular (Emeritus)
Seattle, Washington



Disclosures

Robert M. Bersin, MD

Abbott Vascular C, P, SB
Ablative Solutions EI
Boston Scientific AB, C, EI, P, SB
Cook Medical, Inc. C, P
Med Alliance SA, AB, EI
Medtronic, Inc. C, P
Nectero Medical C, EI
Omeros Corp, EI
QT Vascular, EI
Transverse Medical AB, EI, SO
W.L. Gore C, P

AB: Advisory Board
C: Consulting Relationship
EI: Equity Interest
GS: Grant Support
P: Proctor or Training Course Sponsorships
SB: Speakers Bureau
SE: Spouse Employee
SO: Stock Options or Positions

Drug Coated Balloons
Coronary Devices

Company	Device	Drug	Coating / Excipient	Drug Dose µg/mm²	CE
Aachen Resonance	Elutax SV	PTX	None	2	Yes
Bard	Lutonix 014 PTCA	PTX	Polysorbate / Sorbitol	2	No
B Braun	Sequent Please	PTX	Iopromide	3	Yes
Biotronik	Pantera Lux	PTX	Butyryl-tri-hexyl Citrate	3	Yes
Boston Scientific	Agent	PTX	Acetyl-tri-butyl Citrate	2	Yes
Cardionovum	Restore / Primus	PTX	Shellac	3	Yes
Eucatech	Support C	PTX	Butyryl-tri-hexyl Citrate	3	Yes
Eurocor / Biosensors	DIOR/ BioStream	PTX	Shellac	3	Yes
Medtronic	IN.PACT Falcon	PTX	Urea	3.5	Yes
Minvasys	Danubio	PTX	Butyryl-tri-hexyl Citrate	2.5	Yes
Nano Therapeutics	Curex PTCA	PTX		2.3	No

Drug Coated Balloons
Peripheral Devices

Company	Device	Drug	Coating / Excipient	Drug Dose µg/mm²	CE
Aachen Resonance	Elutax SV	PTX	None	2	Yes
Balton	mcPCB	PTX		3	No
Bard	Lutonix	PTX	Polysorbate / Sorbitol	2	Yes
Bayer-Medrad	Cotavance	PTX	Iopromide	3	Yes
Biotronik	Passeo-18 Lux	PTX	Butyryl-tri-hexyl Citrate	3	Yes
Boston Scientific	Ranger	PTX	Citrate Ester	2	Yes
Cardionovum	Legflow	PTX	Shellac	3	Yes
Cook	Advance 18 PTX	PTX	None	3	Yes
Covidien	Stellarex	PTX	Amphiphilic Polymer	2	Yes
Eurocor / Biosensors	Freeway / BioPath	PTX	Shellac	3	Yes
iVascular	Luminor	PTX	Water Reducer Ester	3	Yes
Medtronic	IN.PACT	PTX	Urea	3.5	Yes
Meril	Mozec	PTX	Nano-particles	3	No
Nano Therapeutics	Curex PTA	PTX		2.3	No
Vascular Nanotransfer Technologies		PTX	Nano-encapsulation		No
Surmodics		PTX	Microcrystalline	3	No
AngioScore	AngioSculpt*	PTX		3	No
TriReme Medical	Chocolate Touch*	PTX			No

Advantages and Disadvantages of Paclitaxel Drug Coated Balloons

Advantages

- Leave nothing behind – preserves treatment options
- Excellent mid-term patency & freedom from TLR
  - Emerging catch up at four years
- All peripheral DCB experience is with paclitaxel

Disadvantages

- No class effect
- Reduced effectiveness in calcified lesions
- Flaking of coatings and particulate embolization
- Safety of paclitaxel in sub-intimal PTA & DAART

Paclitaxel Tissue Toxicity

- Tissue effects of paclitaxel and sirolimus in a vessel cuff animal model
  - Paclitaxel results in loss of smooth muscle cells and reduces collagen content as compared to sirolimus
  - Explains lack of safety of paclitaxel DCBs in sub-intimal PTA and DAART?

Table 2 Comparison of histological findings of cuffed femoral artery segments from 14-day control DEC, SEC and PEC (14 days normal cuff plus 14 days DEC)

	TUNEL+ cells (%)		SMC content (%)		Collagen content (%)			
	Media	Intima	Media	Intima	Media	Intima	IEL disruption¶	Medial macrophage¶
Control DEC	0.27 (0.24)	0.39 (0.24)	25.2 (2.3)	30.8 (2.7)	28.3 (4.9)	40.7 (2.4)	2.2 (0.6)	1.08 (0.08)
1% SEC	1.99 (0.68)	0.58 (0.24)	27.5 (2.7)	28.0 (1.1)	24.0 (3.4)	28.0 (5.8)	2.0 (0.5)	1.39 (0.15)
2.5% SEC	1.78 (0.77)	0.42 (0.21)	16.9 (2.9)*†	21.8 (2.8)	24.0 (3.1)	32.9 (4.9)	2.2 (0.5)	1.49 (0.16)*
1% PEC	0.84 (0.79)	0.95 (0.56)	2.6 (0.9)*†‡	10.3 (1.7)*†	18.6 (1.4)	19.0 (2.1)*‡	3.4 (0.4)	2.20 (0.39)*
2.5% PEC	19.2 (5.7)*†‡§	3.1 (3.08)	3.8 (0.9)*†‡	9.4 (3.1)*†	12.7 (2.0)*†‡	12.4 (6.4)*‡	5.2 (0.6)*†‡§	2.26 (0.33)*

Pires 2007

Sirolimus Drug Coated Balloons

- **Sirolimus offers potential benefits over Paclitaxel:**

Attribute	Sirolimus (or Analogs)	Paclitaxel
Mode of action	**Cytostatic**	**Cytotoxic**
Margin of safety	**10’000 fold**	**100 fold**
Therapeutic range	**Wide**	**Narrow**
Anti-restenotic	**Yes – lower late lumen loss**	**Yes**
Anti-inflammatory	**Yes**	**No**
Tissue absorption	***Slow***	***Fast***
Tissue retention	***Short***	***Long***

- **Sirolimus is *drug of choice* for coronary DES supported by solid clinical based evidence**

Sirolimus Coated Balloons – Challenges

- **Enhance tissue absorption**
  - Difficult to get sirolimus to enter into arterial tissue within 30 to 180 seconds of balloon dilatation; hence some kind of "**instant glue**" is required to transfer the drug from the balloon to the tissue efficiently

- **Extend tissue retention**
  - Sirolimus must be continuously delivered over time, so some form of "**time release mechanism**" must be employed to maintain therapeutic levels

Sirolimus Coated Balloons - Landscape

Company	Product	Drug	Concentration	Excipient
Abbott Vascular	NA	zotarolimus	6-7 μg/mm^2	iopromide matrix
Caliber Therapeutics	Virtue DCB	sirolimus 40-250 nm nanospheres	3 mg	weeping balloon with PLGA-PEG-PLGA triblock polymer coating
Concept Medical	Magic Touch DCB Xtreme Touch DCB	Crystalline sirolimus 50-300 nm nanospheres	1.3 μg/mm^2 3.0 μg/mm^2	phospholipid excipient
Med Alliance SA	Selution DCB	sirolimus 1.5-8 micron microspheres	1.0 μg/mm^2	PDLA with CAT-cell adherence technology
Sahajanand Medical Technologies	NA	sirolimus	0.7 μg/mm^2	PLGA/PVP 50-50 coating

SELUTION™ Sirolimus DCB

- Micro-reservoirs made out of biodegradable polymer intermixed with Sirolimus:
  - Controlled and sustained drug release mechanism
  - Maintains therapeutic effect in tissue over long period of time



- Novel Cell Adherent Technology – CAT™:
  - CAT™ transfer membrane houses and protects micro-reservoirs during balloon insertion, lesion crossing and expansion
  - CAT™ transfer membrane with embedded micro-reservoirs releases from balloon delivery system and adheres to vessel lumen with short balloon inflations

SELUTION™ CAT Technology





Scanning Electron Microscopy at 24 hr



SELUTION™ Sirolimus DCB

Drug Delivery and Dispersion



	Med Alliance SELUTION	Bard LUTONIX	Medtronic IN.PACT
Lost during procedure	36%	83%	83%
Retained on balloon	25%	12%	14%
Transferred to vessel (1 hr)	39%	5%	3%

Med Alliance – Bench Test Data on File
Bard-LUTONIX & Medtronic-IN.PACT – Granada J CRT 2014

SELUTION™ Sirolimus DCB

Drug Dosing and Tissue Drug Levels





Med Alliance – PK Study (2014-004)
Medtronic –Melder RJ LINC 2012
Bard – Catheter Cardiovasc Interv 2014; 83:132–140

SELUTION™ FIH Trial

ClinicalTrials.gov ID: NCT02941224

Objective	To assess clinical safety and inhibition of restenosis of SELUTION™ DCB in treatment of Superficial Femoral (SFA) or Popliteal (PA) Artery lesions
Design	▫ Prospective, Controlled, Multi-Center, Open, Single Arm ▫ N=60
Primary Endpoint	▫ **Angiographic Late Lumen Loss (LLL) by QVA** ▪ **6 months**
Secondary Endpoints	▫ Major Adverse Events (Death, TLR, Amputation) ▪ 6 months ▫ Primary Patency – Freedom from CD-TLR and Restenosis by DUS ▪ 6, 12 and 24 months ▫ Angiographic Binary Restenosis (ABR) by QVA ▪ 6 months ▫ Composite of Freedom from Amputation and Freedom from CD-TVR ▪ 12 and 24 months ▫ Change of ABI, WIQ and QoL ▪ 6, 12 and 24 months

SELUTION™ Trial Design

Enrollment: Oct 26th 2016 – May 23rd 2017



SELUTION™ FIH Trial Management

Trial Centers:

Herzzentrum Bad Krozingen T. Zeller (PI)
Franziskus Krankenhaus, Berlin K. Brechtel
Vivantes Klinikum Neukoelln, Berlin T. Albrecht
Hubertus Krankenhaus, Berlin D. Meyer

Independent CEC committee:

P. Gaines, M. Lichtenberg, G. Tepe

CRO — MD-CLINICALS

Core lab — coreLab BLACK FOREST

Sponsor — Med Alliance Swiss. Medical. Technology.

SELUTION™ FIH Trial

Baseline Clinical Characteristics

Clinical Characteristics	N=50
Age, Y ± SD	69.6 ± 10.4
Male, % (n)	58 % (29)
Previous Intervention, % (n)	30 % (13)
Myocardial Infarction, % (n)	6 % (3)
Renal Insufficiency, % (n)	22 % (11)
Hypertension, % (n)	80 % (40)
Hyperlipidemia, % (n)	90 % (45)
Diabetes (Type 2), % (n)	28 % (14)
Smoking History, % (n)	58 % (29)
Anticoagulation Therapy	22 % (11)
Angina Pectoris	14 % (7)

Lesion Characteristics	N=50
De Novo	96 % (48)
Lesion Length, mm ± SD	64.30 ± 42.8
RVD, mm ± SD	5.1 ± 0.8
% Diameter Stenosis, % ± SD	90 ± 8.0
Occlusion	30% (15)
Calcification	
None	12 % (6)
Mild	44 % (22)
Moderate	10 % (5)
Moderately severe	26 % (13)
Severe	8 % (4)
Target Lesion Location, % (n)	
SFA prox	12 % (6)
SFA mid	34 % (17)
SFA dist	54 % (27)
POP 1	24 % (12)
POP 2/ POP 3/ TPT	16 % (8)

SELUTION™ FIH Trial

Late Lumen Loss at 6 Months

Primary Endpoint

ITT	SELUTION
Underwent 6M Clinical FU - N (%)	43 (86%)
Underwent 6M QVA – N (%)	34 (68%)
LLL (mm)	**0.19 (-1.16;3.07)**
cd TLR - % (N)	2.3 % (1)
Cumulative Clinical Events	
Death	0%
Major or Minor Amputation	0%
Change in Rutherford Class	
Improvement	73%
None	27%
Worsening	0%

SELUTION™ FIH Trial

Late Lumen Loss at 6 Months



0.19 mm*
(-1.16; 3.07)

*Median value

SELUTION™ FIH Trial

Clinical Results in Context





Trial	RANGER SFA	PACIFIER	Tepe et al	LEVANT I	FemPac	BIOLUX-PI	ILLUMENATE	SELUTION
Therapy	Ranger	IN.PACT Pacific	DCB not specified	Lutonix	Ptx coated	Passeo-18 Lux	Stellarex	SELUTION
Mean Lesion Length (mm)	6.8	7.0	5.7	8.1	5.7	6.1	7.2	6.4
Bailout Stenting (%)	21%	21%	11%	3%	9%	N/A	5%	8%

Ranger SFA – Scheinert, D. CIRSE 2016.
PACIFIER – Werk, M. et al. Circ Cardiovasc Interv. 2012; 5(6):831-840.
Tepe, G. et al. J Endovasc Ther. 2015:727-33.
LEVANT I – Scheinert, D. et al. JACC Cardiovasc Interv. 2014;7(1):10-9.
FemPac – Werk, M. et al. Circulation. 2008;118(13):1358-65
BIOLUX PI – Scheinert, D. et al. J Endovasc Ther. 2015;22(1):14-21
ILLUMENATE - Schroeder, H. et al Catheter Cardiovasc Intervent. 2015;86(2):278-86
SELUTION – Zeller, T. LINC 2018

SELUTION FIH Trial

Rutherford, WIQ & ABI







SELUTION™ FIH Trial

Baseline Characteristics Long Lesions

Lesion Characteristics	Overall Population (mean 6.4 cm) N=50	Long Lesion Subset (>8 cm) N = 12
Lesion Length, mm ± SD	51.30 ± 40.34	112.05 ± 25.31
RVD, mm ± SD	5.1 ± 0.8	4.62 ± 0.38
% Diameter Stenosis, % ± SD	90 ± 8.0	91.6 ± 14.13
Occlusion	30% (15)	58% (7)
Calcification		
None	12 % (6)	8 % (1)
Mild	44 % (22)	42 % (5)
Moderate	10 % (5)	0% (0)
Moderately severe	26 % (13)	33% (4)
Severe	8 % (4)	17% (2)
Target Lesion Location, % (n)		
SFA prox	12 % (6)	0 % (0)
SFA mid	34 % (17)	58 % (7)
SFA dist	54 % (27)	25 % (3)
POP 1	24 % (12)	8 % (1)
POP 2/ POP 3/ TPT	16 % (8)	8 % (1)

SELUTION™ FIH Trial

Long Lesion 6-mo Late Loss*



0.23 mm*
(-0.99; 1.25)

*Post-hoc analysis

SELUTION™ FIH Trial

Long Lesion 6-mo Late Loss*



*Late Lumen Loss presented as median values

SELUTION™ FIH Trial Conclusions

- First demonstration of sirolimus safety and efficacy in peripheral interventions
- Met the primary endpoint of LLL (0.19mm) at 6-months
- SELUTION 6-month clinical outcomes are non-inferior to other FIH studies using paclitaxel balloons
- Low 6-month CD TLR 2.2%
- Excellent outcomes despite 34% moderate or heavy Ca^{+2}
- A long lesion subgroup demonstrated similar performance compared to the overall cohort
- Further studies are required to confirm these findings in larger patient populations